Foundation Medicine, Agios developing diagnostics for cancer drugs

04/5/2013 | GenomeWeb Daily News (free registration)

Foundation Medicine and Agios Pharmaceuticals agreed to jointly develop companion diagnostics for the latter's experimental cancer drugs. The two companies will seek to identify genomic mutations to determine which patients will benefit from Agios' new cancer metabolism inhibitors that target tumors with mutated IDH1 or IDH2 metabolic enzymes.

View Full Article in:

GenomeWeb Daily News (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
European Sales Manager
SentreHEART, Inc.
Germany, Benelux, UK
REG AFFAIRS PROJ MGR - 1400000A7F
Abbott
San Jose, CA
SPECIALIST II SYSTEMS INTEGRATION - 140000033P
Abbott
Dallas, TX
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD